中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 6
Jun.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(6): 1287-1293

Application value of simplified diagnosis and treatment strategies for chronic hepatitis C in human immunodeficiency virus/hepatitis C virus co-infection

DOI: 10.12449/JCH260609
  • 1.

    Division of HIV/AIDS and STI Control，Centers for Disease Control and Prevention of Yuxi，Yuxi，Yunnan 653100，China

  • 2.

    Department of Infectious Diseases，People’s Hospital of Yuxi City，Yuxi，Yunnan 653100，China

  • 3.

    Office of Party and Government Affairs，Yuxi Maternal and Child Health Hospital，Yuxi，Yunnan 653100，China

  • 4.

    School of Public Health，Dali University，Dali，Yunnan 671000，China

Research funding:

“Xingyu Talent Earmarked Project” Youth Talent Research Project in Yuxi City (XYYC202534);

Special Program for Medical and Health Talent Development in Yunnan Province (YNYW2026015)

More Information
  • Corresponding author: DONG Wenbin， 815525268@qq.com （ORCID： 0009-0003-3503-9829）; LI Shifu， shifu208@163.com （ORCID： 0009-0003-7175-0482）
  • Received Date: 2025-12-22
  • Accepted Date: 2026-03-13
  • Published Date: 2026-06-25
    Abstract
  •   Objective  To investigate the efficacy and safety of simplified diagnosis and treatment strategies and regimens in the treatment of patients with human immunodeficiency virus （HIV）/hepatitis C virus （HCV） co-infection.  Methods  This multicenter prospective real-world study was conducted among 198 patients with HIV/HCV co-infection who received hepatitis C treatment in 10 designated primary hospitals for hepatitis C in Yuxi， China from July 2023 to June 2024， and according to whether genotype detection was performed， they were divided into genotype detection group with 122 patients and non-genotype detection group with 76 patients. The patients were observed in terms of sustained virologic response at 12 weeks （SVR12）， safety， and liver biochemical parameters. Propensity score matching was used to match the two cohorts， using caliper matching （caliper value = 0.02） at a ratio of 1∶1. The independent-samples t test or the Wilcoxon signed-rank test was used for comparison of continuous data between two groups， and the chi-square test was used for comparison of categorical data between groups.  Results  Among the 122 patients in the genotype detection group， 63.11% （77/122） had genotype 3， while the non-genotype detection group had 76 patients； both groups achieved an SVR12 rate of 100%. From baseline to 12 weeks after treatment， both groups had a significant increase in the serum level of albumin， significant reductions in the serum levels of total bilirubin， alanine aminotransferase， aspartate aminotransferase， and alpha-fetoprotein， and a significant reduction in FibroScan value （all P<0.05）. A total of 54 patients （27.27%） experienced at least one adverse reaction， and anemia was the most common adverse reaction （38 patients， 19.19%）， with an incidence rate of 50.00% （33/66） in patients with liver cirrhosis. HIV viral load remained <50 IU/mL before and after treatment， and there was no significant change in CD4+ T lymphocyte count after treatment （Z=-0.969， P=0.202）. Compared with the genotype detection group， the non-genotype detection group had a significantly shorter time from positive HCV RNA testing to treatment initiation （4±2 days vs 19±4 days， t=5.321， P<0.05） and significantly lower testing costs （618±97 yuan vs 789±129 yuan， t=3.661， P<0.05）.  Conclusion  For patients with HIV/HCV co-infection， the simplified diagnosis and treatment strategies can achieve a relatively high SVR12 rate， improve biochemical indicators， and effectively reduce time cost and economic burden， with a favorable safety profile.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[EB/OL].( 2018-07-01)[ 2025-10-11]. https://www.who.int/publications/i/item/9789241550345. https://www.who.int/publications/i/item/9789241550345
    [2]
    DONG DB, ZOU SQ, TANG S, et al. Visualization analysis of hot spots in direct antiviral therapy of hepatitis C[J]. Chin J AIDS STD, 2023, 29( 8): 881- 886. DOI: 10.13419/j.cnki.aids.2023.08.08.

    董邓波, 邹圣强, 唐舒, 等. 丙型病毒性肝炎直接抗病毒药物治疗研究热点可视化分析[J]. 中国艾滋病性病, 2023, 29( 8): 881- 886. DOI: 10.13419/j.cnki.aids.2023.08.08.
    [3]
    LI J, LIU ZF. Advances, achievements, and challenges in action to eliminate hepatitis C as a public health threat in China[J]. J Clin Hepatol, 2025, 41( 2): 216- 220. DOI: 10.12449/JCH250204.

    李健, 刘中夫. 中国消除丙型肝炎公共卫生危害行动进展、成效与挑战[J]. 临床肝胆病杂志, 2025, 41( 2): 216- 220. DOI: 10.12449/JCH250204.
    [4]
    FOUNDATION CAD. Polaris Observatory HCV Collaborators[EB/OL].( 2024-04-01)[ 2025-10-11]. https://cdafound.org/polaris-countries-dashboard/. https://cdafound.org/polaris-countries-dashboard/
    [5]
    XU YW. Efficacy, prognosis and factors influencing the treatment of genotype 3 chronic hepatitis C with DAAs in a real-world Setting in Yunnan[D]. Dali: Dali University, 2023.

    徐艳雯. 云南地区真实世界中DAAs治疗基因3型慢性丙型肝炎的疗效、预后及影响因素[D]. 大理: 大理大学, 2023.
    [6]
    ZENG QL, JI FP. Interpretation of guideline for the prevention and treatment of hepatitis C(2022 version): Antiviral therapy for special populations[J]. J Clin Hepatol, 2023, 39( 7): 1560- 1563. DOI: 10.3969/j.issn.1001-5256.2023.07.008.

    曾庆磊, 纪泛扑.《丙型肝炎防治指南(2022年版)》解读: 特殊人群抗病毒治疗[J]. 临床肝胆病杂志, 2023, 39( 7): 1560- 1563. DOI: 10.3969/j.issn.1001-5256.2023.07.008.
    [7]
    ZHANG W, ZHAI S, DU H, et al. Efficacy and safety of the 12-week sofosbuvir-coblopasvir regimen in treatment of chronic hepatitis C[J]. J Clin Hepatol, 2023, 39( 3): 539- 545. DOI: 10.3969/j.issn.1001-5256.2023.03.009.

    张伟, 翟嵩, 杜虹, 等. 12周索磷布韦联合可洛派韦治疗慢性丙型肝炎的效果和安全性分析[J]. 临床肝胆病杂志, 2023, 39( 3): 539- 545. DOI: 10.3969/j.issn.1001-5256.2023.03.009.
    [8]
    ZHANG W, ZHAI S, DU H, et al. Efficacy and safety of the 12-week sofosbuvir-coblopasvir regimen in treatment of chronic hepatitis C[J]. J Clin Hepatol, 2023, 39( 3): 539- 545. DOI: 10.3969/j.issn.1001-5256.2023.03.009.

    张伟, 翟嵩, 杜虹, 等. 12周索磷布韦联合可洛派韦治疗慢性丙型肝炎的效果和安全性分析[J]. 临床肝胆病杂志, 2023, 39( 3): 539- 545. DOI: 10.3969/j.issn.1001-5256.2023.03.009.
    [9]
    YANG YR, LI HW, ZHAO ZR, et al. Clinical efficacy and safety of sofosbuvir and vipatavir in the treatment of patients with chronic hepatitis C and HCV/HIV co-infection[J]. J Kunming Med Univ, 2021, 42( 7): 130- 136. DOI: 10.12259/j.issn.2095-610X.S20210722.

    杨永锐, 李海雯, 赵智蓉, 等. 索磷布韦维帕他韦治疗不同基因型慢性丙型肝炎患者和HCV/HIV合并感染患者的临床疗效与安全性[J]. 昆明医科大学学报, 2021, 42( 7): 130- 136. DOI: 10.12259/j.issn.2095-610X.S20210722.
    [10]
    QIU LX, YU HB, LIN W, et al. A real-world study of the efficacy and safety of sofosbuvir and velpatasvir in the treatment of HCV-infected patients in a county in northern China[J]. Chin J Hepatol, 2022, 30( 4): 395- 401. DOI: 10.3760/cma.j.cn501113-20200729-00430.

    仇丽霞, 于海滨, 林伟, 等. 一项索磷布韦维帕他韦治疗中国北方某县HCV感染者有效性和安全性的真实世界研究[J]. 中华肝脏病杂志, 2022, 30( 4): 395- 401. DOI: 10.3760/cma.j.cn501113-20200729-00430.
    [11]
    AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association; Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS(2021 edition)[J]. Chin J Intern Med, 2021, 60( 12): 1106- 1128. DOI: 10.3760/cma.j.cn112138-20211006-00676.

    中华医学会感染病学分会艾滋病丙肝学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中华内科杂志, 2021, 60( 12): 1106- 1128. DOI: 10.3760/cma.j.cn112138-20211006-00676.
    [12]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Infect Dis, 2023, 41( 1): 29- 46. DOI: 10.3760/cma.j.cn311365-20230217-00045.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 29- 46. DOI: 10.3760/cma.j.cn311365-20230217-00045.
    [13]
    World Health Organization. Updated recommendations on HCV simplified service delivery and HCV diagnostics: Policy brief. 1st ed.[EB/OL].( 2022-06-24)[ 2025-10-11]. https://www.who.int/news/item/24-06-2022-WHO-publishes-updated-guidance-on-hepatitis-C-infection https://www.who.int/news/item/24-06-2022-WHO-publishes-updated-guidance-on-hepatitis-C-infection
    [14]
    HUANG CF, IIO E, JUN DW, et al. Direct-acting antivirals in East Asian hepatitis C patients: Real-world experience from the REAL-C Consortium[J]. Hepatol Int, 2019, 13( 5): 587- 598. DOI: 10.1007/s12072-019-09974-z.
    [15]
    WUBULIAISHAN MMTJ, YU H, AIBI AMN, et al. Clinical effect of sofosbuvir-velpatasvir on treatment of patients with genotype 3 chronic hepatic C and liver cirrhosis[J]. Chin J Nosocomiology, 2025, 35( 9): 1322- 1326. DOI: 10.11816/cn.ni.2025-241376.

    买买提江·吾布力艾山, 余虹, 阿米乃·艾比, 等. 索磷布韦/维帕他韦治疗基因3型慢性丙型肝炎和肝硬化患者的临床疗效[J]. 中华医院感染学杂志, 2025, 35( 9): 1322- 1326. DOI: 10.11816/cn.ni.2025-241376.
    [16]
    TANG X. Exploration and research on the“1+1+N” hepatitis C treatment and management model in Yongchuan district, Chongqing[D]. Chongqing: Chongqing Medical University, 2024.

    唐鑫. 重庆市永川区“1+1+N”丙型肝炎治疗管理模式的探索研究[D]. 重庆: 重庆医科大学, 2024.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (40) PDF downloads(16) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return